Description: Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Home Page: www.achillestx.com
245 Hammersmith Road
London,
W6 8PW
United Kingdom
Phone:
44 20 8154 4600
Officers
| Name | Title |
|---|---|
| Dr. Iraj Ali Ph.D. | CEO & Director |
| Dr. Sergio A. Quezada Ph.D. | Founder & Chief Scientific Officer |
| Mr. Robert Coutts | Chief Financial Officer |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Lee M. Stern | Vice President of Investor Relations & External Communications |
| Mr. Daniel Carey Cazel Hood | General Counsel & Company Secretary |
| Julia Wilson | Head of Communications |
| Mr. Tariq Ahmed | Executive Vice President of People |
| Mr. Edward Samuel | Executive Vice President of Technical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3964 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 204 |